MRI for Prostate Cancer
Recruiting in Palo Alto (17 mi)
+44 other locations
Overseen ByClare Tempany-Afdhal
Age: 18+
Sex: Male
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: ECOG-ACRIN Cancer Research Group
Disqualifiers: Claustrophobia, Metallic objects, Renal failure, others
No Placebo Group
Approved in 3 jurisdictions
Trial Summary
What is the purpose of this trial?This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Multiparametric Magnetic Resonance Imaging (mpMRI) for prostate cancer?
Research shows that mpMRI is effective in accurately locating prostate cancer, improving risk assessment, and aiding in treatment decisions. It helps in diagnosing, staging, and evaluating treatment responses, making it a valuable tool in managing prostate cancer.
12345Is multiparametric MRI safe for humans?
The research articles do not provide specific safety data for multiparametric MRI, but it is widely used in prostate cancer detection and monitoring, suggesting it is generally considered safe.
678910How is multiparametric MRI different from other treatments for prostate cancer?
Multiparametric MRI (mpMRI) is unique because it is a non-invasive imaging technique that provides detailed functional information about the prostate, helping to accurately distinguish between benign and malignant lesions. Unlike other treatments, it serves as a highly effective diagnostic tool, improving the localization of prostate cancer and aiding in better clinical decision-making.
13111213Eligibility Criteria
This trial is for men recently diagnosed with prostate cancer who are candidates for definitive surgery. It's not open to those who've had previous treatments for prostate cancer, major pelvic surgeries like hip replacements, or can't have an MRI due to severe claustrophobia, certain metal implants, kidney failure, or exceeding the scanner's weight limit.Inclusion Criteria
I have recently been diagnosed with prostate cancer and need surgery.
Exclusion Criteria
I have had a hip replacement or major surgery in my pelvic area.
Participant Groups
The study is testing how well a type of advanced imaging called multiparametric MRI works in assessing the stage of prostate cancer and aiding in treatment planning. The goal is to see if this MRI technique can better identify aggressive types of prostate cancer.
1Treatment groups
Experimental Treatment
Group I: Diagnostic (mpMRI)Experimental Treatment1 Intervention
Patients undergo mpMRI within 3 months prior to schedule surgery.
Multiparametric Magnetic Resonance Imaging is already approved in European Union, United States, Canada for the following indications:
🇪🇺 Approved in European Union as Multiparametric MRI for:
- Prostate cancer staging
- Prostate cancer treatment planning
- Active surveillance of low-risk prostate cancer
🇺🇸 Approved in United States as Multiparametric MRI for:
- Prostate cancer detection
- Prostate cancer staging
- Prostate cancer treatment planning
- Active surveillance of low-risk prostate cancer
🇨🇦 Approved in Canada as Multiparametric MRI for:
- Prostate cancer detection
- Prostate cancer staging
- Prostate cancer treatment planning
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Dartmouth Hitchcock Medical CenterLebanon, NH
Thomas Jefferson University HospitalPhiladelphia, PA
Fox Chase Cancer CenterPhiladelphia, PA
Corewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids, MI
More Trial Locations
Loading ...
Who is running the clinical trial?
ECOG-ACRIN Cancer Research GroupLead Sponsor
National Cancer Institute (NCI)Collaborator
References
Detection of individual prostate cancer via multiparametric magnetic resonance imaging in own material - initial experience. [2022]Multiparametric magnetic resonance imaging (mpMRI) is an evolving non-invasive imaging modality that increases the accurate localization of prostate cancer (PCa) at the time of MRI targeted biopsy, enhancing clinical risk assessment, and improving the ability to appropriately counsel patients regarding therapy.
The role of multi-parametric MRI in loco-regional staging of men diagnosed with early prostate cancer. [2015]To review the use of multi-parametric MRI (mpMRI) in loco-regional assessment of men with early prostate cancer.
Education of prostate MR imaging: commentary. [2021]Multiparametric MRI (mpMRI) of the prostate has been firmly established as a tool in the diagnosis, management, and treatment of prostate cancer. The growth in this field over the past decade has led to increased acceptance and demand for multiparametric prostate MRI across the world. However, with the rising demand for prostate mpMRI, it will become increasingly necessary to train a generation of dedicated prostate imagers to yield a high-quality product.
Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy. [2021]Multiparametric magnetic resonance imaging (mpMRI) facilitates the detection of significant prostate cancer. Therefore, addition of mpMRI to clinical parameters might improve the prediction of extraprostatic extension (EPE) in radical prostatectomy (RP) specimens.
Prostate MRI: staging and decision-making. [2021]Multi-parametric prostate MRI (mpMRI) plays a critical role in the diagnosis, staging, and evaluation of treatment response in patients with prostate cancer. Radiologists, through an accurate and standardized interpretation of mpMRI, can clinically stage prostate cancer and help to risk stratify patients who may benefit from more invasive treatment or exclude patients who may be harmed by overtreatment. The purpose of this article is to describe key findings to accurately stage prostate cancer with mpMRI and to describe the contexts in which mpMRI is best applied.
Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance. [2020]To characterize the use of multiparametric magnetic resonance imaging (mpMRI) in male Medicare beneficiaries electing active surveillance for prostate cancer. mpMRI has emerged as a tool that may improve risk-stratification and decrease repeated biopsies in men electing active surveillance. However, the extent to which mpMRI has been implemented in active surveillance has not been established.
Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study. [2018]To assess whether non-suspicious multiparametric magnetic-resonance imaging (mpMRI) was associated with no cancer or indolent prostate cancer (PCa) in subsequent biopsies.
Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. [2020]To review the role of multiparametric magnetic resonance imaging (mpMRI) for active surveillance (AS) of prostate cancer.
Feasibility of Multiparametric Magnetic Resonance Imaging of the Prostate at 7 T. [2018]The aim of this study was to evaluate the technical feasibility of prostate multiparametric magnetic resonance imaging (mpMRI) at a magnetic field strength of 7 T.
What You Need to Know Before Reading Multiparametric MRI for Prostate Cancer. [2020]OBJECTIVE. Multiparametric MRI (mpMRI) has become the main imaging modality for the detection, localization, and local staging of prostate cancer over the past decade. For radiologists to achieve consistent and reproducible reporting of prostate mpMRI, a comprehensive evaluation of the gland including detailed knowledge of anatomy, pathology, and clinical data is required. This article familiarizes radiologists with common pitfalls and conditions that affect mpMRI performance during readouts. CONCLUSION. Consistent, accurate, and reproducible reporting of prostate mpMRI is vital. Additionally, radiologists should be aware of common diagnostic pitfalls that can hinder mpMRI performance.
Dramatic increase in the utilization of multiparametric magnetic resonance imaging for detection and management of prostate cancer. [2022]Multiparametric MRI (mpMRI) of the prostate is an evolving technology that provides functional information of the prostate that helps distinguish benign from malignant lesions. We hypothesized that mpMRI is rapidly adopted in the US to fill the unmet need for a non-invasive, accurate screening tool. The aim of this study is to assess the increasing utilization of mpMRI for the diagnosis and management of prostate cancer.
The future direction of imaging in prostate cancer: MRI with or without contrast injection. [2022]Multiparametric MRI (mpMRI) is the "state of the art" management tool for patients with suspicion of prostate cancer (PCa). The role of non-contrast MRI is investigated to move toward a more personalized, less invasive, and highly cost-effective PCa diagnostic workup.
Short review of biparametric prostate MRI. [2020]Magnetic resonance imaging (MRI) of the prostate has become the gold standard for visualization of prostate cancer. Prostate MRI is usually performed as multiparametric MRI (mpMRI). Since mpMRI has several drawbacks, a biparametric MRI (bpMRI) of the prostate has been proposed. Many studies have been published on mpMRI and bpMRI in recent years. This short review offers an overview of the latest developments in this rapidly evolving field of research.